By Anthony O. Goriainoff
Glanbia, the Irish nutrition group, announced an increase in pretax profit for the first half of fiscal 2024. This boost was attributed to an exceptional net post-tax gain. However, the company has revised its revenue guidance for Glanbia Performance Nutrition (GPN) for the year.
New CEO Appointment
Hugh McGuire, currently the CEO of GPN, will be appointed as the new chief executive officer effective Jan. 1.
Financial Performance
For the six months ending July 1, Glanbia's pretax profit reached $214 million, compared to $157.6 million the previous year. During this period, the company recorded an exceptional net post-tax gain of $56.5 million. Adjusted earnings before interest, taxes and amortization (EBITA) were up by 6.1% on a constant currency basis, reaching $198.6 million.
Decrease in Revenue
Glanbia experienced a decline in revenue, falling from $3.09 billion to $2.77 billion. This decrease can be attributed to lower volumes, a 12% decrease in price, as well as reductions related to mergers and acquisitions.
Revised Guidance
The company expects revenue growth for the GPN division to be at the lower end of the previously guided range of 5% to 7% on a constant currency basis. However, Glanbia upgraded its full-year EBITA margin expectations to be between 13.5% and 14.5%. Additionally, adjusted earnings per share growth for the year has been revised to between 12% and 15% based on an improved outlook for GPN. The initial forecast in March predicted adjusted EPS growth of 5% to 10%.
Our Latest News
Eurozone Economy Grows Slightly Surpassing Expectations
Preliminary data reveals eurozone economy grew by 0.3% in Q2, with better-than-expected growth in France and Spain while some major members experienced contract...
Nvidia's Quarterly Earnings Impress Analysts
Nvidia's quarterly earnings exceed expectations, leading to a surge in stock price. Analysts praise the company's performance and upgrade their ratings. Concern...
BioNTech's Q2 Revenue Misses Expectations, Shares Fall
Shares of BioNTech dropped as Q2 revenue falls short of expectations due to write-offs by Pfizer, leading to lower profit share. The company remains optimistic...